PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
Clinical trial NCT05175742 · COMPLETED
Trial details
- NCT number
- NCT05175742
- Sponsor
- Providence Therapeutics Holdings Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-17
- Primary completion
- 2023-03-29
- Enrollment
- 565
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.